PDE-5 inhibitors increase risk of biochemical recurrence after radical prostatectomy
the ONA take:
According to a new study published in The Journal of Urology, researchers have found that taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of biochemical recurrence.
Phosphodiesterase type 5 inhibitors include sildenafil, tadalafil, and vardenafil, and are indicated for the treatment of pulmonary hypertension and erectile dysfunction.
Researchers at University Hospital Hamburg-Eppendorf in Hamburg, Germany, sought to investigate the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence following a radical prostatectomy in patients with prostate cancer.
Researchers analyzed data from nearly 5,000 patients with localized prostate cancer who underwent bilateral nerve-sparing radical prostatectomy. Of those, 23.4% used phosphodiesterase type 5 inhibitors following surgery.
During a median follow-up of 60.3 months, there was a 5-year biochemical recurrence-free survival of 84.7% in the phosphodiesterase type 5 inhibitor group compared with 89.2% in the nonphosphodiesterase type 5 inhibitor group. Multivariate analysis showed that phosphodiesterase type 5 inhibitor use was an independent risk factor for biochemical recurrence (HR = 1.38).
Taking phosphodiesterase type 5 inhibitors following radical prostatectomy is associated with an elevated risk of recurrence.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|